Status:
UNKNOWN
Quality of Life for Subjects Receiving Androgen Deprivation Therapy and Have a Doubling in PSA of Either Less Than or Greater Than 1 Year
Lead Sponsor:
Urology South Shore Research Inc.
Collaborating Sponsors:
AstraZeneca
Conditions:
Prostate Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
The purpose of this study is to evaluate if there is a difference in quality of life (as measured by FACT-P) in patients treated with androgen deprivation therapy (ADT) for biochemical failure (PSA re...
Eligibility Criteria
Inclusion
- 18 years or older
- Received therapy of curative intent (surgery or radiotherapy)
- Have a rising PSA which has doubled from a nadir value.
- Histologically proven prostate cancer requiring androgen deprivation therapy for at least 12 months
- Written informed consent to participate in the trial.
Exclusion
- Known hypersensitivity to Zoladex, Casodex, ar any component of these products
- Prior treatment with LHRH agonist or anti-androgens in the past 12 months
- Any concomitant condition that would make it undesirable, in the physician's opinion, for the subject to participate in the trial or would jeopardize compliance with the protocol.
Key Trial Info
Start Date :
June 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2010
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00703768
Start Date
June 1 2006
End Date
July 1 2010
Last Update
February 17 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Urology South Shore Research Inc.
Greenfield Park, Quebec, Canada, J4V 2H3